Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Naresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 22, pp. 2702-2712
Open Access | Times Cited: 18

Showing 18 citing articles:

Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways
Alexander Eggel, Luke F. Pennington, Theodore S. Jardetzky
Immunological Reviews (2024)
Open Access | Times Cited: 10
Bispecific antibodies in the treatment of multiple myeloma
Anup J. Devasia, Ajai Chari, Guido Lancman
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Extramedullary Myeloma in the Era of CAR T-cell and Bispecific Antibody Therapies
Larysa Sanchez, Shambavi Richard
Seminars in Hematology (2025)
Closed Access | Times Cited: 1
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Susanna Kim, Adam ElSayed, Jonathan E. Moore, et al.
Targeted Oncology (2025)
Closed Access
Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma
Joshua Richter, Madhav V. Dhodapkar, Mengying Li, et al.
American Journal of Hematology (2025)
Closed Access
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
Zachary M. Avigan, Mohammad Rattu, Joshua Richter
Expert Opinion on Biological Therapy (2025)
Closed Access
Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study
Sikander Ailawadhi, Timothy J. Inocencio, Carol Mansfield, et al.
Future Oncology (2025), pp. 1-13
Open Access
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
Shaji Kumar, Xavier Leleu, Katja Weisel, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens?
Sofía I. Quezada-Ramírez, Luz Tarín‐Arzaga, Andrés Gómez‐De León, et al.
Expert Review of Hematology (2025)
Closed Access
Antibodies to watch in 2025
Silvia Crescioli, Hélène Kaplon, Lin Wang, et al.
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
Zhen Wang, Yanqi Song, Honglei Guo, et al.
Current Treatment Options in Oncology (2025)
Closed Access
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
Sabarish Ayyappan, Jeremy T. Larsen, James F. Sanchez, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Kevin G. Shim, Rafaël Fonseca
Cancers (2024) Vol. 16, Iss. 19, pp. 3288-3288
Open Access | Times Cited: 1
Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives
Johannes M. Waldschmidt, Leo Rasche, K. Martin Kortüm, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
Tarek H. Mouhieddine, Bruno Almeida Costa, Joshua Richter
Seminars in Hematology (2024)
Closed Access | Times Cited: 1
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
Xiaojie Liang, Yufan Wang, Baiwei Luo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e010064-e010064
Open Access
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management
David Kegyes, Vlad Moisoiu, Cătălin Constantinescu, et al.
Blood Reviews (2024) Vol. 69, pp. 101254-101254
Closed Access
Anticuerpos biespecíficos en el mieloma múltiple en recaída
Carlos Fernández-de Larrea, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, et al.
Revista Sangre (2024) Vol. 43, Iss. 92
Closed Access
Bispecific antibody targets and therapies in multiple myeloma
Matthew Rees, Nadine Abdallah, Binoy Yohannan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top